GlassScriptPhysician profile
William F Buchner
NPI 1154304574
$17,572.14
in general payments reported to CMS, 2019-2025
39 companies · $2,661 in 2025
The $2,661 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,269 · 2020: $1,422 · 2021: $2,232 · 2022: $2,924 · 2023: $2,556 · 2024: $3,510 · 2025: $2,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,618 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,618.23 |
| Education | $107.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,432.68 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,987.25 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,126.56 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $797.55 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $749.40 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $615.52 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $541.85 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $479.08 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $440.35 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Gilead Sciences, INC. | $367.91 | 2019-2025 | Livdelzi |
| Regeneron Healthcare Solutions, INC. | $363.70 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $361.27 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $311.61 | 2021-2023 | |
| Madrigal Pharmaceuticals | $303.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $263.16 | 2019-2024 | Linzess |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $228.07 | 2024-2025 | Zenpep |
| Evoke Pharma, INC. | $193.29 | 2022-2024 | Gimoti |
| Daiichi Sankyo INC. | $131.34 | 2023-2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $109.53 | 2024 | Iqirvo, Bylvay |
| Intra-Sana Laboratories | $106.98 | 2022 | |
| Intercept Pharmaceuticals, INC. | $74.02 | 2020-2023 | Ocaliva |
| Braintree Laboratories, INC. | $64.14 | 2019-2024 | Suflave |
| Boston Scientific Corporation | $62.84 | 2020-2025 | Exalt Model D |
| Allergan, INC. | $62.73 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $60.27 | 2020-2022 | |
| Novo Nordisk INC | $55.57 | 2023-2025 | Wegovy |
| Romark Laboratories, Lc | $44.75 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.45 | 2023-2024 | Cyltezo |
| Lilly USA, LLC | $29.48 | 2024 | Omvoh |
| Celltrion USA INC. | $28.63 | 2023-2024 | Zymfentra, Yuflyma |
| Medtronic, INC. | $28.08 | 2023-2024 | Interstim, Gi Genius |
| Amgen INC. | $19.65 | 2023 | Avsola, Amjevita |
| Shire North American Group INC | $18.20 | 2019 | |
| Fresenius Kabi USA, LLC | $16.93 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $15.97 | 2025 | Givlaari |
| Capsovision, INC. | $15.79 | 2023 | Capsocam Plus |
| Kaleo, INC. | $14.55 | 2019 | |
| Celgene Corporation | $12.84 | 2021 | |
| Organon LLC | $5.80 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Buchner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.